In a filing, Esperion Therapeutics Inc. revealed its Chief Commercial Officer Warren Eric unloaded Company’s shares for reported $344.0 on Aug 18. In the deal valued at $1.41 per share,243 shares were sold. As a result of this transaction, Warren Eric now holds 69,060 shares worth roughly $ 0.11 million.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Then, Warren Eric sold 106 shares, generating $168 in total proceeds. Upon selling the shares at $1.58, the Chief Commercial Officer now owns 69,303 shares.
Before that, Warren Eric sold 603 shares. Esperion Therapeutics Inc. shares valued at $894 were divested by the Chief Commercial Officer at a price of $1.48 per share. As a result of the transaction, Warren Eric now holds 69,409 shares, worth roughly $0.11 million.
Northland Capital upgraded its Esperion Therapeutics Inc. [ESPR] rating to a Market perform from a an Under perform in a research note published on Friday.
Price Performance Review of ESPR
On Friday, Esperion Therapeutics Inc. [NASDAQ:ESPR] saw its stock fall -2.50% to $1.56. On the same session, the stock had its day’s lowest price of $1.54, but rose to a high of $1.66. Over the last five days, the stock has gained 13.04%. Esperion Therapeutics Inc. shares have fallen nearly -74.96% since the year began. Nevertheless, the stocks have fallen -79.09% over the past one year. While a 52-week high of $8.87 was reached on 01/10/23, a 52-week low of $1.12 was recorded on 04/26/23. SMA at 50 days reached $1.5230, while 200 days put it at $3.4054. A total of 2.88 million shares were traded, compared to the trading of 4.14 million shares in the previous session.
Levels Of Support And Resistance For ESPR Stock
The 24-hour chart illustrates a support level at 1.5133, which if violated will result in even more drops to 1.4667. On the upside, there is a resistance level at 1.6333. A further resistance level may holdings at 1.7067. The Relative Strength Index (RSI) on the 14-day chart is 51.53, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0781, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 49.52%. Stochastics %K at 55.56% indicates the stock is a holding.
How much short interest is there in Esperion Therapeutics Inc.?
A steep rise in short interest was recorded in Esperion Therapeutics Inc. stocks on Aug 14, 2023, growing by 0.96 million shares to a total of 13.99 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 13.03 million shares. There was a rise of 6.86%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 15.96% of the overall stock float, the days-to-cover ratio (short ratio) rose to 4.93.
Esperion Therapeutics Inc. [ESPR] – Who Are The Largest Shareholders?
In filings from Wasatch Advisors, Inc., it is revealed that the company now owns 13,139,556 shares, or roughly 13.87% of the outstanding ESPR shares. In other words, the investor’s shares have fallen by -214,630 from its previous 13-F filing of 13354186.0. Additionally, Armistice Capital LLC increased 149.86% of its stake after which the total value it holdings stand at $14,433,010, while Millennium Management LLC added 60.35% of its stake to hold $8.43 million in the firm. Over the last quarter, Point72 Asset Management LP purchased 1,375,000 shares of Esperion Therapeutics Inc., while Meditor Capital Management Ltd. bought 0 shares. At present, The Vanguard Group, Inc. is holding 4,238,993 shares valued at $6.66 million. Bellevue Asset Management AG owned 4,208,264 shares of the company at the time of its most recent 13F filing, worth $6.61 million.
However, 9 analysts have rated ESPR stock as a Buy in their predictions for 2023.